TL;DR
The emerging and relatively consistent evidence showing that select polyphenols positively modulate a variety of contributors to the NAFLD phenotype, through diverse and complementary mechanisms of action is reviewed.
The most common type of chronic liver disease is non-alcoholic fatty liver disease (NAFLD), which has become a significant worldwide health concern. Western eating patterns are characterized by diets high in fats and sugar, which disrupt redox balance, promote inflammatory responses, and impair normal liver function. E...
Type 2 diabetes mellitus (T2D) represents over 90% of diabetes cases globally, posing a growing public health crisis with an estimated 783 million adults projected to be affected by 2045. This condition arises from a complex interplay of insulin resistance, progressive pancreatic β-cell dysfunction, and chronic low-gra...
Metabolic Syndrome (MetS) encompasses several conditions, including central adiposity, insulin resistance, dyslipidemia, hypertension, and fatty liver. In recent years, extensive research has been conducted on new non-pharmacological treatments for each of these conditions. This work analyzes the beneficial effects...
Aim. To review current data on the effect of incretin mimetics on the course of metabolically associated fatty liver disease. Key points. In obesity, the liver is exposed to the negative effects of excessive lipid accumulation. This process underlies metabolically associated liver disease (MAFLD), a condition that ent...
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease and is closely associated with obesity, insulin resistance, and the recently conceptualized cardiovascular–kidney–metabolic syndrome. For decades, the pathogenesis of steatosis has been viewed primarily through the...
The terminology of fatty liver disease has evolved from non-alcoholic fatty liver disease (NAFLD) to alternative metabolically oriented frameworks, including metabolic dysfunction-associated fatty liver disease (MAFLD) and, more recently, metabolic dysfunction-associated steatotic liver disease (MASLD). Its complex pat...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
